AARTIDRUGS vs GLAND: Stock Comparison

Aarti Drugs Limited vs Gland Pharma Limited

Live data: 22 July 2026, 3:07 PM IST • Source: NSE and company filings

Gland Pharma Limited is the larger company by market capitalisation. Aarti Drugs Limited shows a lower P/E and a higher ROE, while Gland Pharma Limited shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarti Drugs Limited and Gland Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AARTIDRUGS is more favourable on 3 of 13 scored metrics and GLAND on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GLAND is the larger company
₹40,471 Cr vs ₹3,769 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
20.04x vs 39.81x
P/B Ratio
AARTIDRUGS has a lower P/B
2.52x vs 3.95x
EPS
GLAND has higher earnings per share
₹62.22 vs ₹21.81
Dividend Yield
GLAND has a higher dividend yield
0.81% vs 0.48%
Revenue Growth (TTM YoY)
GLAND has faster revenue growth
22.3% vs 6.4%
EPS Growth (TTM YoY)
GLAND has faster EPS growth
96.4% vs -12%
Qtr Sales Growth
GLAND has stronger quarterly sales growth
22.3% vs 6.43%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSGLAND
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSGLAND
Live Price₹411.15₹2,441.6
Day Change-3.69%-1.64%
Volume2.96 L6.17 L
52-Week High₹551.75₹2,573.5
52-Week Low₹318.95₹1,573.6
Distance from 52W High-25.48%-5.13%

Valuation

MetricAARTIDRUGSGLAND
Market Cap₹3,769 Cr₹40,471 Cr
P/E Ratio20.04x39.81x
P/B Ratio2.52x3.95x
EPS₹21.81₹62.22
Book Value₹169.79₹628.81
Dividend Yield0.48%0.81%

Growth

MetricAARTIDRUGSGLAND
Revenue Growth (TTM YoY)6.4%22.3%
EPS Growth (TTM YoY)-12%96.4%
Qtr Sales Growth6.43%22.3%
Qtr Profit Growth-12.2%96.6%

Profitability & Leverage

MetricAARTIDRUGSGLAND
ROE13.4%10.7%
ROCE11.9%15.1%
Net Margin7.6%16.18%
Operating Margin12%25.3%
Debt to Equity0.37x0.03x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAARTIDRUGSGLAND
Promoter Holding55.03%51.83%
FII Holding1.58% 0.57 pp7.3% 0.28 pp
DII Holding10.22% 0.1 pp33.35% 0.37 pp
Public Holding33.18% 0.48 pp7.52% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarti Drugs Limited and Gland Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.